Loading…
Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. It also sells and rents HME devices, such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment. In addition, the company provides neuromuscular care and oxygen therapy services; and sleep apnea management which provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, it offers in-home sleep apnea testing services; and breast pumps and related lactation equipment and supplies, including fulfillment and support services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $270M | $52M | $15M | $12M | 10.4% | 20.5% | 32.6% |
| 2024 | $224M | $42M | $11M | $1M | 8.5% | 22.5% | 10.0% |
| 2023 | $183M | $37M | $10M | $19M | 9.0% | 31.8% | 64.6% |
| 2022 | $139M | $25M | $6M | $5M | 6.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 138.83 | 183.01 | 224.26 | 270.28 |
| Cost Of Revenue | 54.15 | 70.22 | 91.05 | 114.82 |
| Gross Profit | 84.68 | 112.78 | 133.20 | 155.46 |
| Operating Expense | 76.08 | 97.81 | 117.21 | 134.75 |
| Operating Income | 8.60 | 14.97 | 15.99 | 20.71 |
| EBITDA | 24.82 | 36.68 | 42.31 | 51.56 |
| EBIT | 9.19 | 14.81 | 16.95 | 22.95 |
| Pretax Income | 8.99 | 14.39 | 16.17 | 21.77 |
| Tax Provision | 2.77 | 4.15 | 4.76 | 6.39 |
| Net Income | 6.22 | 10.24 | 11.27 | 14.93 |
| Net Income Common Stockholders | 6.22 | 10.24 | 11.27 | 14.93 |
| Total Expenses | 130.23 | 168.03 | 208.26 | 249.57 |
| Interest Expense | 0.20 | 0.42 | 0.78 | 1.18 |
| Research And Development | 2.70 | 2.78 | 3.07 | 3.02 |
| Selling General And Administration | 73.36 | 93.73 | 112.48 | 130.50 |
| Normalized EBITDA | 25.16 | 36.84 | 41.36 | 49.32 |
| Normalized Income | 6.46 | 10.36 | 10.59 | 13.35 |
| Basic EPS | 0.16 | 0.27 | 0.29 | 0 |
| Diluted EPS | 0.16 | 0.25 | 0.28 | 0 |
| Tax Effect Of Unusual Items | -0.11 | -0.05 | 0.28 | 0.66 |
| Tax Rate For Calcs | 0.31 | 0.29 | 0.29 | 0.29 |
| Total Unusual Items | -0.35 | -0.16 | 0.95 | 2.24 |
| Total Unusual Items Excluding Goodwill | -0.35 | -0.16 | 0.95 | 2.24 |
| Net Income From Continuing Operation Net Minority Interest | 6.22 | 10.24 | 11.27 | 14.93 |
| Reconciled Depreciation | 15.63 | 21.86 | 25.37 | 28.61 |
| Reconciled Cost Of Revenue | 39.53 | 49.75 | 67.17 | 87.69 |
| Net Interest Income | -0.20 | -0.42 | -0.78 | -1.18 |
| Net Income From Continuing And Discontinued Operation | 6.22 | 10.24 | 11.27 | 14.93 |
| Total Operating Income As Reported | 8.25 | 14.33 | 17.90 | 22.95 |
| Diluted Average Shares | 39.81 | 40.38 | 40.81 | 0 |
| Basic Average Shares | 38.66 | 38.35 | 38.75 | 0 |
| Diluted NI Availto Com Stockholders | 6.22 | 10.24 | 11.27 | 14.93 |
| Minority Interests | 0 | 0 | -0.14 | -0.44 |
| Net Income Including Noncontrolling Interests | 6.22 | 10.24 | 11.41 | 15.38 |
| Net Income Continuous Operations | 6.22 | 10.24 | 11.41 | 15.38 |
| Other Income Expense | 0.59 | -0.16 | 0.95 | 2.24 |
| Special Income Charges | -0.35 | -0.65 | 1.91 | 2.24 |
| Gain On Sale Of Ppe | -0.35 | -0.65 | 1.91 | 2.24 |
| Earnings From Equity Interest | 0.94 | 0.48 | -0.95 | 0 |
| Gain On Sale Of Security | 0 | 0.48 | -0.95 | 0 |
| Net Non Operating Interest Income Expense | -0.20 | -0.42 | -0.78 | -1.18 |
| Total Other Finance Cost | 0 | 0 | 0 | 0 |
| Interest Expense Non Operating | 0.20 | 0.42 | 0.78 | 1.18 |
| Other Operating Expenses | -0.99 | -0.10 | 0.17 | -0.25 |
| Depreciation Amortization Depletion Income Statement | 1.01 | 1.39 | 1.48 | 1.49 |
| Depreciation And Amortization In Income Statement | 1.01 | 1.39 | 1.48 | 1.49 |
| Depreciation Income Statement | 1.01 | 0 | 0 | 0 |
| General And Administrative Expense | 73.36 | 93.73 | 112.48 | 130.50 |
| Other Gand A | 68.16 | 87.88 | 106.20 | 121.37 |
| Salaries And Wages | 5.20 | 5.85 | 6.29 | 9.13 |
| Operating Revenue | 138.83 | 183.01 | 224.26 | 270.28 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Viemed Healthcare, Inc.this co. | VMD | $381M | 26.73↓ discount | 2.66 | 10.4% | 7.66 |
| TruBridge, Inc. | TBRG | $386M | 88.72 | 2.10 | 2.4% | 13.37 |
| Weave Communications, Inc. | WEAV | $385M | - | 4.61 | -34.1% | -18.58 |
| Cerus Corporation | CERS | $385M | - | 5.75 | -24.1% | -52.90 |
| Niagen Bioscience, Inc. | NAGE | $381M |
| 23.80 |
| 4.97 |
| 22.7% |
| 21.23 |
| Puma Biotechnology, Inc. | PBYI | $381M | 12.26 | 2.89 | 23.9% | 6.57 |
| Rocket Pharmaceuticals, Inc. | RCKT | $380M | - | 1.36 | -80.5% | -0.98 |
| OrthoPediatrics Corp. | KIDS | $376M | - | 1.06 | -11.4% | -53.45 |
| NRC Health | NRC | $373M | 42.41 | 26.76 | 82.9% | 12.41 |
| Peer Median | - | 33.11 | 3.75 | -4.5% | 2.79 | |